CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Parabilis Medicines, Inc.

PBLS
$4.26BMid Cap

Next catalyst

Phase 2April 2027

FOG-001

Cancer

Get an email about PBLS's next catalysts

Track Parabilis Medicines (PBLS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 2Next

FOG-001 Phase 2 Est. Readout

April 2027~FOG-001619

Estimated primary completion for FOG-001 trial (NCT05919264) in Cancer. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaCAMBRIDGE145 employees
Drug Pipeline

Frequently asked questions

What is in Parabilis Medicines, Inc.'s drug pipeline?β†’

CatalystAlert tracks 2 drug candidates in Parabilis Medicines, Inc.'s (PBLS) pipeline across Phase 2. Its lead program is FOG-001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Parabilis Medicines, Inc.'s next FDA catalyst?β†’

Parabilis Medicines, Inc.'s (PBLS) next tracked catalyst is a Phase 2 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track PBLS biotech catalysts?β†’

Add PBLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Parabilis Medicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply